Compare Mesoblast Limited (MESO) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs WD 40 Company — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while WD 40 Company trades at $233.59 (market cap $3.15B). The key difference: WD 40 Company is the larger of the two by market cap, and WD 40 Company pays a 1.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WDFC | |
|---|---|---|
Market Cap | $2.16B | $3.15B |
Sector | Technology | Technology |
52-Week High | $20.96 | $264.91 |
52-Week Low | $12.88 | $187.52 |
Enterprise Value | $2.17B | $3.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
WDFC trades at $234.93, up 1.61% today, with a bullish technical outlook supported by moving averages but neutral oscillators. Recent Q2 2026 earnings beat expectations at $2.33 EPS, though Q4 2025 missed. The company maintains strong profitability with a 55.82% gross margin and 13.22% net margin, while valuation ratios like P/E of 35.64 suggest a premium. A quarterly dividend of $1.02 was declared, payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support growth, but high input costs pressure margins. Risks include competitive threats and valuation concerns. Analyst consensus is cautious with 71.42% hold ratings. Upside hinges on margin stability and execution of clear growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
